首页 News 正文

In the fourth quarter, Lilly's revenue was $9.35 billion, exceeding market expectations of $8.96 billion, with a year-on-year increase of 28%. Lilly's GLP-1 drug Zepbound is expected to dominate the weight loss market in 2024. However, Lilly faced limited production capacity in 2023 and took measures to increase supply in 2024.
您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

123458026 新手上路
  • 粉丝

    0

  • 关注

    0

  • 主题

    4